PTPRC and leukemia: Notably, the sh-ZNF217 group showed a significant reduction in fluorescence signal intensity compared to the control group (Figure 4B-C), along with a decrease in fluorescence intensity in both the liver and spleen (Figure 4E-F) and discernible reductions in the proportions of bone and liver/spleen CD45+ cells (Figure 4G, Figure S9B), indicating a reduced leukemia burden in the sh-ZNF217 group.